Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The low-prevalence Rh antigen, JAL, was named after the index case, Mr. J. Allen. Based on reactivity of seven multi-specific sera with his RBCs, it was apparent that they express at least one additional low-prevalence antigen. The purpose of this study was to investigate the other low-prevalence antigen(s) on J. Allen's RBCs.
Methods: Blood samples and reagents were from our collections. Hemagglutination and DNA analyses were performed by standard methods.
Results: Our DNA analyses confirmed the presence of RHCE*ceS(340T) in J. Allen and revealed the presence of RHCE*ceBI (ce 48C, 712G, 818T, 1132G) and RHD*DOL (509T, 667T). RBCs from J. Allen were agglutinated by anti-JAL, anti-STEM, and anti-DAK. Two of the reactive multi-specific sera reported in the original paper reacted with RBCs from J. Allen, and with RBCs from four other people with RHCE*ceBI, including the original STEM+ index case (P. Stemper) but not with RBCs with the DIIIa, DAK+ phenotype. We conclude that they contain anti-STEM.
Conclusion: J.Allen's RBCs express the low-prevalence Rh antigens, JAL, V/VS (extremely weakly), STEM, and DAK. The presence of JAL on the variant Rhce, RhceJAL (16Cys, 114Trp, 245Val), STEM on the variant Rhce, RhceBI (16Cys, 238Val, 273Val, 378Val), and DAK on the variant RhD (170Thr, 223Val), encoded by RHD*DOL in trans to RHCE*ceBI is consistent with expression of these antigens. When J. Allen RBCs are used to detect and identify an anti-JAL, it is important to remember that they also express STEM and DAK.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115496 | PMC |
| http://dx.doi.org/10.1111/j.1423-0410.2010.01465.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening and eradication of or gastric cancer prevention: Taipei Global Consensus II.
Gut
September 2025
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Objective: To convene a global consensus on () screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions.
Methods: 32 experts from 12 countries developed and refined consensus statements on management, using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to assess evidence and the Delphi method to achieve ≥80% agreement.
Results: Consensus was achieved on 28 statements.
Platelet-Related Biomarkers and Efficacy of Antiplatelet Therapy in Patients with Aortic Stenosis and Coronary Artery Disease.
Int J Mol Sci
July 2025
First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-635 Katowice, Poland.
The objective of this study was to evaluate the serum biomarkers implicated in the interaction of platelets and endothelium, as well as the efficacy of antiplatelet therapy in patients with aortic stenosis (AS) and coronary artery disease (CAD). A total of 78 adult patients with CAD on aspirin therapy participated in this study, including 49 consecutive patients with AS and 29 control subjects. The analysis included the following serum biomarkers: thrombomodulin (TM), platelet factor 4 (PF4), P-selectin, and CD40L.
View Article and Find Full Text PDFPrevalence of Dal blood type and dog erythrocyte antigens 1 and 4 among canine blood donors and recipients in Seoul, South Korea.
BMC Vet Res
August 2025
Department of Veterinary Emergency and Critical Care, College of Veterinary Medicine, Konkuk University, Seoul, 05029, Republic of Korea.
Background: The demand for blood transfusions in veterinary medicine is increasing in South Korea, particularly for canine patients. While dog erythrocyte antigen (DEA) 1 is a known cause of acute hemolytic reactions, previous studies have underscored the involvement of DEA 4 and Dal. However, research on these crucial antigens remains limited in South Korea compared to North America and Europe, resulting in a knowledge gap concerning transfusion risks.
View Article and Find Full Text PDFResolving Uncertainty in Hepatitis B Diagnosis: Evaluating Neutralization Testing for Borderline HBsAg.
Ann Clin Lab Sci
May 2025
Department of Laboratory Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Objective: To assess the performance of neutralization confirmatory testing for borderline hepatitis B surface antigen (HBsAg) results (signal-to-cutoff [S/CO] 1.0-10.0) in a low-prevalence population.
View Article and Find Full Text PDFDiagnostic Accuracy of a SARS-CoV-2 Antigen Test Obtained by Mid-turbinate Nasal Swabs.
Cureus
July 2025
Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, USA.
Context In the early months of the COVID-19 pandemic, polymerase chain reaction (PCR) testing for SARS-CoV-2 was difficult to obtain and took several days to return a result. Our health system wished to explore the use of the Quidel Sofia (Quidel Corporation, San Diego, CA) antigen test to diagnose COVID-19 in our primary care clinics, but the test was approved for emergency use authorization by the US Food and Drug Administration (FDA) with only 250 test subjects. In addition, because it was important to avoid aerosol-generating procedures in primary care clinics, it was necessary to test the diagnostic performance of the antigen test using mid-turbinate (MT) swabs rather than the approved nasopharyngeal (NP) swab technique.
View Article and Find Full Text PDF